Antibiotics can disrupt gut microbiota, leading to potential recurrences of Clostridioides difficile infections (CDI). New therapies like fecal microbiota transplantation (FMT) and monoclonal ...

Fecal microbiota transplantation (FMT), shown to be effective in the treatment of recurrent Clostridioides difficile infection (CDI), also shows significant benefit in the treatment of primary CDI, ...

Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk factors ...

The U.S. Food and Drug Administration (FDA) has approved VOWST, a microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibacterial treatment for ...

The antibiotic vancomycin, recommended as first-line treatment for infection caused by the deadly superbug C. difficile (C. diff), may not be living up to its promise, according to new research. The ...

C. diff is a horrible disease that can cause significant morbidity. It can and often does recur and kills around 30,000 Americans every year. We have made progress in prevention and treatment, but ...

A new study from the University of Birmingham has shown that Faecal Microbiota Transplants (FMT) are highly successful in treating patients with Clostridioides difficile (C.diff) infection. Published ...

Clostridium difficile bacteria, computer illustration. C. difficile is a normal inhabitant of the human intestine, but it can become a pathogen when antibiotics disrupt the normal intestinal flora and ...

Shares of Seres Therapeutics Inc. jumped 14.2% in premarket trading on Tuesday after the company shared data from a Phase 3 open-label study that confirmed the safety and efficacy of its experimental ...

In vitro, treatment with UDCA significantly decreased C. diff spore germination, growth and toxin activity. In the mouse model, pre-treatment with UDCA had some effect on bacterial growth, but the ...

Charles Darkoh, Ph.D., a researcher at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, was recently awarded a five-year, $1.9 million R01 grant by the ...